Introduction
Glucagon-like peptides (GLPs) and glucagon are hormones encoded by the same gene, proglucagon, each having different physiological activities 1 . Due to alternative posttranslational processing, glucagon is predominantly produced in endocrine pancreatic α-cells by Prohormone Convertase (PC)-2 whereas GLPs are predominantly produced in the intestine and also the brain after cleavage by PC-1/3 2,-4 . Glucagon stimulates hepatic glucose production to maintain blood glucose levels upon fasting 5 and inhibits insulin gene expression in pancreatic β-cells 6 . Intestinal L cell GLP-1 is primarily produced during the postprandial state to promote β-cell insulin secretion to decrease α-cell glucagon secretion 7 .
The role of GLP-1 in the metabolic response to glucose ingestion has been established by several studies both in human and animal models. Acute administration of a GLP-1 antagonist leads to increased blood glucose levels in humans 8 , whereas GLP-1 receptor gene disruption in mice results in glucose intolerance 9,-11 . The insulinotropic activity of GLP-1 is preserved in type 2 diabetes 12,-14 , but is reduced compared to healthy subjects 14, 15 . Treatment of diabetic patients with GLP-1 increases meal-stimulated insulin levels and suppresses postprandial hyperglycaemia without causing hypoglycaemia 16, 17 . However, circulating GLP-1 has a very short half-life due to inactivation by the enzyme dipeptidyl peptidase IV . The potential of GLP-1 for the treatment of diabetes has led to the development of long-acting DPPIVresistant GLP-1 analogs and orally bioavailable DPP-4 inhibitors, both approaches having proven efficacy in lowering blood glucose levels and HbA 1c in patients with type 2 diabetes 14, 18 .
However, an alternative approach may be to increase endogenous GLP-1 production through modulation of proglucagon gene transcription in enteroendocrine L cells.
The proglucagon promoter contains several transcriptional control elements localized in the 2.5-kb 5'-upstream sequence of the transcriptional initiation site 19 . A number of transcription factors control proglucagon gene expression in a tissue-specific manner allowing physiologically appropriate regulation of the production of the different active peptides 20 . The transcription factor Pax6 activates proglucagon gene transcription in α-cells by binding the G1 response element in the proglucagon promoter 21, 22 . Disruption of the murine Pax6 gene not only markedly disrupts islet development, but also selectively eliminates enteroendocrine cell populations in the intestine including the subpopulation of GLP-1-producing cells, indicating the importance of Pax6 also in the control of intestinal proglucagon gene expression 23 . By contrast, the G2 response element of the proglucagon promoter appears involved in the tissue-specific regulation of proglucagon transcription since protein kinase C activation enhances transcription in α-cells via this site 24 , without influencing intestinal expression 25 .
Moreover, insulin and GSK-3β inhibitors, such as lithium, stimulate G2 response element activity specifically in enteroendocrine L cells through the β-catenin/TCF-4 signaling pathway resulting in increased GLP-1 production 26, 27 .
The Peroxisome Proliferator-Activated Receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear receptor superfamily which regulate fatty acid, cholesterol and carbohydrate metabolism 28 . Whereas PPARα and PPARγ are the targets of the fibrates and glitazones respectively, the PPARβ/δ isoform appears an interesting pharmacological target for the treatment of disorders associated with the metabolic syndrome 29, 30 . PPARβ/δ-deficient mice challenged with a high-fat diet exhibit obesity 31 and glucose-intolerance 32 . Furthermore, in vivo PPARβ/δ activation reduces body weight and lipid accumulation in adipose tissue and improves insulin sensitivity through increased skeletal muscle fatty acid oxidation 31, 32 .
In this study, we examined the hypothesis that PPARβ/δ activation enhances GLP-1 production by L cells, which would contribute to the improvement of glucose tolerance in vivo.
Our data identify intestinal tissue-specific regulation of proglucagon gene expression as a new mechanism of action for PPARβ/δ in glucose metabolism thus expanding its interest as target for the treatment of type 2 diabetes.
Materials and Methods

Chemicals and reagents. See Supplementary Material.
In Vitro Studies
Cell culture and treatment. The mouse GLUTag L cell model was kindly provided by D.J.Drucker (University of Toronto, Canada). The human NCI-H716 L cell, murine α-TC1/9 α-cells and rat INS1-E β-cells were purchased from ATCC ® (CCL-251™ and CRL-2350™ respectively 
Gene reporter assays. See Supplementary Material.
GLP-1 secretion assays. GLUTag L cells were starved for 30min in glucose-free Krebs-phosphate-buffered medium (120mM NaCl, 5mM KCl, 0.25mM MgCl 2 , 0.5mM CaCl 2 and 2.2mM NaHCO 3 , pH7.2) supplemented with diprotin-A 100µM and BSA 0.1%. Cells were subsequently stimulated for 30min with Krebs buffer in the presence or not of glucose 5mM or a BA mix (50µM each; LCA and DCA). The cell supernatants were centrifuged at 500 x g at 4°C for 5min and GLP-1 measured with Elisa Kit (EGL P-35K, Millipore) using Mithras technology (Berthold).
Western blot analysis. See Supplementary Material.
Ex vivo Studies
Human islet isolation. Human islet isolation and culture conditions were previously described 33, 34 .
Human jejunum tissue isolation. Fresh human jejunum tissue was obtained with informed consent from obese patients undergoing gastric bypass surgery (gastrojejunal derivation) and enrolled in the ABOS study (ClinGov NCT01129297). For details, see Supplementary Material.
Animal Models and Experimental Protocols
PPARβ β β β/δ δ δ δ-deficient and ob/ob mice. [6] [7] [8] week-old male PPARβ/δ-deficient 35 , obese ob/ob and wild-type mice (Charles River laboratories), fed a chow diet (A03; UAR, France) and maintained in a temperature-controlled room (22°C) on a 12h light-dark cycle, were treated by gavage with vehicle or the PPARβ/δ synthetic agonists (GW0742 or GW501516) at the indicated doses and times. Plasma and several tissues including different intestinal sections (duodenum, jejunum, ileum, and colon) and pancreas were collected after 6h fasting.
All tissues were snap-frozen in liquid nitrogen and stored at -80°C until RNA isolation. Animal care and experimental procedures were performed according to approved institutional guidelines (# CEEA 02/2008).
Oral and intra-peritoneal glucose tolerance tests (OGTT, IPGTT). Oral (OGTT) and
intra-peritoneal (IPGTT) glucose tolerance tests were performed on overnight fasted mice.
Sitagliptin was given orally at a dose of 25 mg/kg 45min before the glucose challenge (3g/kg of body weight). For details, see Supplementary Material. 
RNA isolation and quantification by real time-quantitative PCR (RT-QPCR
Results
Glucose is a Positive Modulator of Proglucagon and Prohormone Convertase-1/3 (PC-1/3) Gene Expression in GLUTag L Cells.
Glucose is the primary stimulus for GLP-1 secretion by enteroendocrine L cells.
However, the transcriptional impact of glucose on proglucagon expression has not yet been 
PPARβ β β β/δ δ δ δ Activation in GLUTag L Cells Increases Proglucagon Expression and
Improves Glucose-and BA-Induced GLP-1 Release.
Since PPARβ/δ and PPARγ are expressed in GLUTag L cells, it was next examined whether activation of these PPARs may regulate GLP-1 production. Surprisingly, PPARγ activation with rosiglitazone transiently decreased proglucagon mRNA levels (supplementary Next, it was determined whether the increased proglucagon expression due to PPARβ/δ activation influences GLP-1 production according to the protocol described in Since lithium activates the −350-bp proglucagon promoter in GLUTag L cells via the βcatenin/TCF-4 signaling pathway 26, 27 and since PPARβ/δ activation has been shown to influence the β-catenin/TCF-4 signaling pathway 39 31, 32 . However, the capacity of β-cells to secrete insulin upon glucose challenge was also improved in GW501516-treated ob/ob mice. A significant increase of plasma insulin was observed in GW501516-treated ob/ob mice 15min after glucose tolerance test, which was more pronounced upon oral versus intraperitoneal glucose loading, thus illustrating the enhanced incretin effect after PPARβ/δ activation. By contrast, no significant changes in plasma insulin were found in control ob/ob mice likely due to the pronounced hyperinsulinemic insulin-resistant phenotype (Figure7C) .
PPARβ β β β/δ δ δ δ Activation Increases Proglucagon mRNA Levels and Enhances GLP-1
Release by Human Enteroendocrine L Cells In Vitro and Ex Vivo.
Finally, glucose excursion in the oral glucose tolerance test was improved in GW501516treated ob/ob mice (Figure7D) with a significant reduction of iAUC glucose compared to untreated ob/ob mice ( Figure 7D , inset).
Discussion
Our results show that PPARβ/δ activation positively regulates enteroendrine L cell GLP-1 production and enhances its response to glucose and BAs. Proglucagon mRNA levels and GLP-1 production were markedly increased in PPARβ/δ agonist-treated mice contributing to a significant improvement of glucose homeostasis. Likewise, activation of mouse and human enteroendocrine L cells in vitro or ex vivo with PPARβ/δ agonists significantly increased proglucagon mRNA levels and enhanced glucose-and BA-induced GLP-1 secretion.
As described by Drucker et al. 42, 43 , the murine GLUTag L cell line is a useful model for the analysis of the molecular determinants of enteroendocrine gene expression. We thus used this model and studied the transcriptional regulation of genes whose products participate in GLP-1 production. Our data show that glucose is not only a primary stimulus of GLP-1 release, but it is also a positive transcriptional modulator of proglucagon and PC-1/3 mRNA levels in GLUTag L cells. Moreover, we found that GLUTag L cells express PPARγ and PPARβ/δ at high levels, whereas PPARα is not expressed. A significant decrease of PPARγ was observed in glucose-stimulated GLUTag L cells, whereas no major change of PPARβ/δ expression was observed. Interestingly, proglucagon mRNA levels were significantly decreased in GLUTag L cells treated with the PPARγ agonist rosiglitazone. Additionally, in wild-type mice treated with rosiglitazone, a significant decrease of proglucagon mRNA levels in small intestine was also observed (data not shown). This observation is consistent with results obtained in pancreatic α-cells in which proglucagon gene transcription is also decreased by rosiglitazone treatment through interfering with the Pax6/G1 enhancer element pathway 44, 45 . We thus speculate that the negative rosiglitazone effect on proglucagon gene expression in enteroendocrine L cell may be due to inhibition of the Pax6 pathway, which has an important role in intestinal proglucagon gene expression 23 . In line with these observations, it is reasonable to speculate that PPARγ does not enhance GLP-1 biosynthesis.
Since previous reports have demonstrated that GLP-1 receptor agonists inhibit β-cell apoptosis under conditions of glucolipotoxicity 46, 47 and that PPARβ/δ activation also prevents palmitate-induced β-cell apoptosis 28 Further, it has been established that lithium, a GSK-3β inhibitor, and insulin increase proglucagon expression through stimulation of the β-catenin-TCF/Lef signaling pathway only in enteroendocrine GLP-1-producting L cells, but not in pancreatic glucagon-producing αcells 26, 27 . This is due to the fact that the transcription factor TCF-4 is expressed in small intestine epithelium 39 Previous studies suggested that PPARβ/δ activation is similar to PPARγ activation in their effects on improving insulin sensitivity 32, 49, 50 . PPARβ/δ agonist treatment of diabetic db/db, ob/ob or high fat-fed mice reduces weight gain, increases skeletal muscle fatty acid oxidation and decreases plasma triglycerides 31, 51, 52 . In line with these previous data, our results show that GW501516-treated ob/ob mice also displayed a 10% decrease of body 
